MedTrace Logo

Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

NCT07636863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-06-09

No results posted yet for this study

Summary

This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.

Conditions

Interventions

DRUG

Nivolumab

As per product label

COMBINATION_PRODUCT

Subcutaneous nivolumab combined with hyaluronidase

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-21
Primary Completion
2025-12-22
Completion
2026-03-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07636863 on ClinicalTrials.gov